Cargando…

Efficacy and safety of onabotulinumtoxinA in patients with overactive bladder: subgroup analyses by sex and by serum prostate-specific antigen levels in men from a randomized controlled trial

PURPOSE: We aimed to assess onabotulinumtoxinA treatment outcomes by sex in patients with overactive bladder (OAB) and then explore the impact of serum prostate-specific antigen (PSA) levels in men. METHODS: Patients inadequately managed with OAB medications were randomized to receive single-dose on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yokoyama, Osamu, Honda, Masashi, Yamanishi, Tomonori, Sekiguchi, Yuki, Fujii, Kenji, Kinoshita, Kyoko, Nakayama, Takashi, Ueno, Akikazu, Mogi, Takao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Netherlands 2021
Materias:	Urology - Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494701/ https://www.ncbi.nlm.nih.gov/pubmed/34292493 http://dx.doi.org/10.1007/s11255-021-02962-z

Ejemplares similares

Comparative assessment of onabotulinumtoxinA and mirabegron for overactive bladder: an indirect treatment comparison
por: Freemantle, Nick, et al.
Publicado: (2016)

300 IU vs. 200 IU of OnabotulinumtoxinA for detrusor overactivity
por: Persu, Cristian
Publicado: (2014)

Botulinum toxin injections for Japanese patients with urinary incontinence caused by neurogenic detrusor overactivity: Clinical evaluation of onabotulinumtoxinA in a randomized, placebo‐controlled, double‐blind trial with an open‐label extension
por: Honda, Masashi, et al.
Publicado: (2021)

OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder
por: Sievert, K-D, et al.
Publicado: (2014)

OnabotulinumtoxinA for the treatment of overactive bladder
por: Cox, Lindsey, et al.
Publicado: (2014)

The satisfaction of patients with refractory idiopathic overactive bladder with onabotulinumtoxinA and augmentation cystoplasty
por: El-Azab, Ahmed S., et al.
Publicado: (2013)

Efficacy and safety of intradetrusor onabotulinumtoxinA injection for managing paediatric non-neurogenic overactive bladder: A prospective case-series study
por: El-Dakhakhny, Amr S., et al.
Publicado: (2019)

OnabotulinumtoxinA for the treatment of neurogenic detrusor overactivity in children
por: Austin, Paul F., et al.
Publicado: (2020)

New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA
por: Andersson, Karl-Erik
Publicado: (2013)

Treatment of neurogenic detrusor overactivity and overactive bladder with Botox (onabotulinumtoxinA): Development, insights, and impact
por: Nitti, Victor, et al.
Publicado: (2023)

Intravesical OnabotulinumtoxinA Injection for Overactive Orthotopic Ileal Neobladder: Feasibility and Efficacy
por: Hoag, Nathan, et al.
Publicado: (2016)

OnabotulinumtoxinA for neurogenic detrusor overactivity and dose differences: a systematic review
por: Zhang, Rui, et al.
Publicado: (2015)

Reduced versus standard intradetrusor OnabotulinumtoxinA injections for treatment of overactive bladder
por: DiCarlo‐Meacham, Angela M., et al.
Publicado: (2022)

Editorial Comment: Sacral neuromodulation versus onabotulinumtoxinA for refractory urgency urinary incontinence: impact on fecal incontinence symptoms and sexual function
por: Riccetto, Cássio L. Z.
Publicado: (2020)

Factors Associated with Therapeutic Efficacy of Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Syndrome
por: Hsiao, Sheng-Mou, et al.
Publicado: (2016)

Neurogenic overactive bladder in spinal cord injury and multiple sclerosis: role of onabotulinumtoxinA
por: Ethans, KD, et al.
Publicado: (2014)

von Brunn's Nests and Follicular Cystitis Following Intradetrusor OnabotulinumtoxinA Injections for Overactive Bladder
por: Nekkanti, Silpa, et al.
Publicado: (2017)

Cost-Utility Analysis of Oxybutynin vs. OnabotulinumtoxinA (Botox) in the Treatment of Overactive Bladder Syndrome
por: Shabir, Habiba, et al.
Publicado: (2021)

OnabotulinumtoxinA (botulinum toxin type A) for the treatment of Japanese patients with overactive bladder and urinary incontinence: Results of single‐dose treatment from a phase III, randomized, double‐blind, placebo‐controlled trial (interim analysis)
por: Yokoyama, Osamu, et al.
Publicado: (2020)

Editorial Comment: Long-term outcomes and risks factors for failure of intradetrusor onabotulinumtoxin A injections for the treatment of refractory neurogenic detrusor overactivity
por: Averbeck, Marcio Augusto
Publicado: (2021)

Efficacy and Safety of OnabotulinumtoxinA in Treating Neurogenic Detrusor Overactivity: A Systematic Review and Meta-analysis
por: Zhou, Xin, et al.
Publicado: (2015)

OnabotulinumtoxinA is a well tolerated and effective treatment for refractory overactive bladder in real-world practice
por: Hamid, Rizwan, et al.
Publicado: (2020)

OnabotulinumtoxinA in the treatment of neurogenic bladder
por: Gulamhusein, Aziz, et al.
Publicado: (2012)

Botox (onabotulinumtoxinA) mechanism of action
por: Brin, Mitchell F., et al.
Publicado: (2023)

OnabotulinumtoxinA effects on trigeminal nociceptors
por: Moore, Ashley A, et al.
Publicado: (2023)

Triptan efficacy does not predict onabotulinumtoxinA efficacy but improves with onabotulinumtoxinA response in chronic migraine patients
por: Eren, Ozan E., et al.
Publicado: (2020)

Efficacy and Adverse Events Associated With Use of OnabotulinumtoxinA for Treatment of Neurogenic Detrusor Overactivity: A Meta-Analysis
por: Yuan, Hejia, et al.
Publicado: (2017)

A Feasibility Study to Evaluate Changes in Urinary Metabolites after OnabotulinumtoxinA Injection for Refractory Overactive Bladder
por: Tellechea, Laura M., et al.
Publicado: (2022)

The Effects of Age, Gender, and Postvoid Residual Volume on Catheterization Rates After Treatment with OnabotulinumtoxinA for Overactive Bladder
por: Dmochowski, Roger, et al.
Publicado: (2023)

Pregnancy outcomes following exposure to onabotulinumtoxinA
por: Brin, Mitchell F., et al.
Publicado: (2015)

Cognitive effects of onabotulinumtoxinA in chronic migraine
por: Ho, Susan, et al.
Publicado: (2020)

OnabotulinumtoxinA: Still the Present for Chronic Migraine
por: Baraldi, Carlo, et al.
Publicado: (2023)

Early development history of Botox (onabotulinumtoxinA)
por: Scott, Alan B., et al.
Publicado: (2023)

The pluripotential evolution and journey of Botox (onabotulinumtoxinA)
por: Brin, Mitchell F., et al.
Publicado: (2023)

Efficacy and Safety of Intravesical OnabotulinumtoxinA Injection on Elderly Patients with Chronic Central Nervous System Lesions and Overactive Bladder
por: Jiang, Yuan-Hong, et al.
Publicado: (2014)

Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Patients with Frailty, Medical Comorbidities or Prior Lower Urinary Tract Surgery
por: Liao, Chun-Hou, et al.
Publicado: (2016)

Antibiotic prophylaxis may not be necessary in patients with asymptomatic bacteriuria undergoing intradetrusor onabotulinumtoxinA injections for neurogenic detrusor overactivity
por: Leitner, Lorenz, et al.
Publicado: (2016)

Retrospective Observational Study of Treatment Patterns and Efficacy of onabotulinumtoxinA Therapy in Patients with Refractory Overactive Bladder in Clinical Practice
por: Ko, Kwang Jin, et al.
Publicado: (2023)

What is the feasibility of switching to 200IU OnabotulinumtoxinA in patients with detrusor overactivity who have previously received 300IU?
por: Malki, Manar, et al.
Publicado: (2014)

Cost-Effectiveness Analysis of OnabotulinumtoxinA (BOTOX(®)) for the Management of Urinary Incontinence in Adults with Neurogenic Detrusor Overactivity: A UK Perspective
por: Hamid, Rizwan, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_j6ett1u6v7ft0jpvj0trm04lch